-
公开(公告)号:AU2008300527A1
公开(公告)日:2009-03-26
申请号:AU2008300527
申请日:2008-09-18
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: COUPA SOPHIE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE , SCHOENTJES BRUNO
IPC: C07D401/12 , A61K31/4045 , A61P29/00 , A61P35/00 , C07D401/14
Abstract: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Q and Z have defined meanings.
-
公开(公告)号:MX2009000456A
公开(公告)日:2009-01-27
申请号:MX2009000456
申请日:2007-07-12
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: FREYNE EDDY JEAN EDGARD , WILLEMS MARC , EMBRECHTS WERNER CONSTANT JOHAN , TEN HOLTE PETER , MEVELLEC LAURENCE ANNE , PAPANIKOS ALEXANDRA , STORCK PIERRE-HENRI
IPC: C07D498/14 , A61K31/519 , A61P35/00
Abstract: La presente invención se relaciona con los compuestos de fórmula (I), las formas de N-óxido, las sales de adición farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de los mismos, en donde Y representa -alquilo de C3-9, -alquil de C1-5-NR6-alquilo de C1-5 o -alquil de C1-5-NR7-CO-alquilo de C1-5; X1 representa -O-; X2 representa -NR5-alquilo de C1-2; R1 representa hidrógeno, halo o Het3-O-; R2 representa hidrógeno; R3 representa hidroxi, alquiloxi de C1-4 o alquiloxi de C1-4 sustituido con uno o dos sustituyentes, cada uno seleccionado de manera independiente de Het4, hidroxi, alquiloxi de C1-4, alquiloxi de C1-4-alquiloxi de C1-4 y NR9R10; R5 representa hidrógeno o alquilo de C1-4; R6 representa hidrógeno o alquilo de C1-4; R7 representa hidrógeno; R9 y R10 representan cada uno de manera independiente hidrógeno; alquil de C1-4-S(=O)2-alquil de C1-4-C(=O)-; alquilo de C1-4 o alquilo de C1-4 sustituido con hidroxi; Het3 representa piridinilo sustituido opcionalmente con alquilo de C1-4; Het4 representa morfolinilo, piperidinilo o piperacinilo, en donde el Het4 está sustituido opcionalmente con hidroxialquilo de C1-4 o alquil de C1-4-S(=O)2-alquilo de C1-4.
-
公开(公告)号:CA2678248A1
公开(公告)日:2008-09-12
申请号:CA2678248
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , PILATTE ISABELLE NOELLE CONSTANCE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , DUFFY JAMES EDWARD STEWART , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , PONCELET VIRGINIE SOPHIE , STORCK PIERRE-HENRI , OWENS ANDREW PATE , VIALARD JORGE EDUARDO , MARCONNET-DECRANE LAURENCE FRANCOISE BERNADETTE , MACRITCHIE JACQUELINE ANNE
IPC: C07D215/22 , A61K31/4704
Abstract: The present invention provides compounds of Formula (I), their use as PAR P inhibitors as well as pharmaceutical compositions comprising said compound s, wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
-
公开(公告)号:CA2654583A1
公开(公告)日:2008-01-17
申请号:CA2654583
申请日:2007-07-12
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEN HOLTE PETER , MEVELLEC LAURENCE ANNE , EMBRECHTS WERNER CONSTANT JOHAN , WILLEMS MARC , PAPANIKOS ALEXANDRA , STORCK PIERRE-HENRI , FREYNE EDDY JEAN EDGARD
IPC: C07D498/14 , A61K31/519 , A61P35/00
Abstract: The present invention concerns the compounds of formula (I) the N-oxide f orms, the pharmaceutically acceptable addition salts and the stereochemicall y isomeric forms thereof, wherein Y represents -C3-9alkyl-, -C1-5alkyl-NR6-C 1-5alkyl- or -C1-5alkyl-NR7-CO-C1-5alkyl-; X1 represents -O-; X2 represents NR5-C1-2alkyl-; R1 represents hydrogen, halo or Het3-O-; R2 represents hydro gen; R3 represents hydroxy, C1-4alkyloxy- or C1-4alkyloxy subst ituted with one or two substituents each independently selected from Het4, hydroxy, C1-4 alkyloxy-, C1-4alkyloxy-C1-4alkyloxy and NR9R10; R5 represents hydrogen or C 1-4alkyl; R6 represents hydrogen or C1-4alkyl; R7 represents hydrogen; R9 an d R10 each independently represent hydrogen; C1-4alkyl-S(=O)2-C1-4alkyl-C(=O )-; C1-4alkyl or C1-4alkyl substituted with hydroxy; Het3 represents pyridin yl optionally substituted with C1-4alkyl; Het4 represents morpholinyl, piper idinyl or piperazinyl wherein said Het4 is optionally substituted with hydro xy-C1-4alkyl or C1-4alkyl-S(=O)2-C1-4alkyl-.
-
公开(公告)号:BRPI0817223A2
公开(公告)日:2015-03-10
申请号:BRPI0817223
申请日:2008-09-18
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: PONCELET VIRGINIE SOPHIE , COUPA SOPHIE , STORCK PIERRE-HENRI , SCHOENTJES BRUNO
IPC: C07D401/12 , A61K31/4045 , A61P29/00 , A61P35/00 , C07D401/14
Abstract: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Q and Z have defined meanings.
-
公开(公告)号:AU2008300483B2
公开(公告)日:2013-01-10
申请号:AU2008300483
申请日:2008-09-19
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: STORCK PIERRE-HENRI , PIETTRE ARNAUD MARCEL PIERRE , CSOKA IMRE CHRISTIAN FRANCIS , SCHOENTJES BRUNO , ERMERT PHILIPP , PONCELET VIRGINIE SOPHIE
IPC: C07D413/14 , A61K31/538 , A61P35/00
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, s, t, R
-
公开(公告)号:AT542799T
公开(公告)日:2012-02-15
申请号:AT08717511
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VIALARD JORGE EDUARDO , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , PILATTE ISABELLE NOELLE CONSTANCE , ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , MARCONNET-DECRANE LAURENCE FRANCOISE , MACRITCHIE JACQUELINE ANNE , DUFFY JAMES EDWARD STEWART , OWENS ANDREW PATE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE
IPC: C07D215/22 , A61K31/4704
-
公开(公告)号:AU2008300483A1
公开(公告)日:2009-03-26
申请号:AU2008300483
申请日:2008-09-19
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: STORCK PIERRE-HENRI , SCHOENTJES BRUNO , ERMERT PHILIPP , PIETTRE ARNAUD MARCEL PIERRE , CSOKA IMRE CHRISTIAN FRANCIS , PONCELET VIRGINIE SOPHIE
IPC: C07D413/14 , A61K31/538 , A61P35/00
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, s, t, R1, R2, R3, R4, R5, X, Y, Q, Z, G, E and D have defined meanings.
-
公开(公告)号:CA2699849C
公开(公告)日:2015-10-27
申请号:CA2699849
申请日:2008-09-18
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: PONCELET VIRGINIE SOPHIE , COUPA SOPHIE , STORCK PIERRE-HENRI , SCHOENTJES BRUNO
IPC: C07D401/12 , A61K31/4045 , A61P29/00 , A61P35/00 , C07D401/14
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds; wherein n, m, p, s, t, R1, R2, R3, R4, R, R6, R7, R20, X, Y, Q and Z have defined meanings.
-
30.
公开(公告)号:HRP20150139T1
公开(公告)日:2015-05-22
申请号:HRP20150139
申请日:2015-02-04
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANGIBAUD PATRICK RENÉ , MEVELLEC LAURENCE ANNE , ROUX BRUNO , STORCK PIERRE-HENRI , MEYER CHRISTOPHE , VIALARD JORGE EDUARDO
IPC: C07D221/12 , A61K31/473 , A61P35/00 , C07D401/06
-
-
-
-
-
-
-
-
-